{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:34:31Z","timestamp":1790890471662,"version":"4.1.0"},"reference-count":48,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2011,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Oritavancin is a novel lipoglycopeptide with demonstrated effectiveness against complicated skin and skin structure infections (cSSSI) caused by Gram-positive pathogens, including those caused by methicillin-resistant\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Staphylococcus aureus<\/jats:named-content>\n            (MRSA). The pharmacokinetic and pharmacodynamic profile of oritavancin is favorable for single or infrequent dosing. A phase 2, multicenter, randomized, double-blind, parallel, active-comparator study (ClinicalTrials.gov identifier, NCT00514527) of single and infrequent dosing of intravenous (i.v.) oritavancin for the treatment of cSSSI caused by Gram-positive pathogens (wound infections, major abscess, and cellulitis) was undertaken to evaluate the noninferiority of front-loaded dosing regimens compared to a daily-dosing regimen. A total of 302 patients \u226518 years of age were randomized equally to one of three oritavancin treatment groups, receiving either a daily dose (200 mg) administered for 3 to 7 days, a single dose (1,200 mg), or an infrequent dose (800-mg dose, with the option for an additional 400 mg on day 5). The primary efficacy was defined as a clinical response in clinically evaluable (CE) patients assessed at days 21 to 29 (test of cure [TOC]). The cure rates in the CE population were 72.4% (55\/76) in the daily-dose group, 81.5% (66\/81) in the 1,200-mg-single-dose group, and 77.5% (55\/71) in the infrequent-dose group. In patients with MRSA at baseline, the cure rates were 78.3% (18\/23), 73.0% (27\/37), and 87.0% (20\/23) in the daily-, 1,200-mg-single-, and infrequent-dose groups, respectively; however, the study was not powered to assess outcomes in the MRSA subpopulation, and given the heterogeneity of the types of infection and the small sample size, these do not suggest any true differences in efficacy rates for these pathogens. The frequencies of adverse events were similar among treatment groups. The results of this study show that single- and infrequent-dosing schedules of oritavancin were as efficacious as daily administration and had a similar safety profile in treating cSSSI caused by Gram-positive pathogens, including MRSA.\n          <\/jats:p>","DOI":"10.1128\/aac.00029-11","type":"journal-article","created":{"date-parts":[[2011,5,3]],"date-time":"2011-05-03T02:42:03Z","timestamp":1304390523000},"page":"3476-3484","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":62,"title":["Comparison of the Efficacy and Safety of Oritavancin Front-Loaded Dosing Regimens to Daily Dosing: an Analysis of the SIMPLIFI Trial"],"prefix":"10.1128","volume":"55","author":[{"given":"Lala M.","family":"Dunbar","sequence":"first","affiliation":[{"name":"LSU Health Sciences Center, School of Medicine at New Orleans, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Milata","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ty","family":"McClure","sequence":"additional","affiliation":[{"name":"Infinity Pharmaceuticals, Inc., Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret M.","family":"Wasilewski","sequence":"additional","affiliation":[{"name":"ID Remedies, LLC, Arlington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the SIMPLIFI Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s150100070038"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/420818"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00952-09"},{"key":"e_1_3_2_5_2","volume-title":"E-1567. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother.","author":"Arhin F. F.","year":"2010","unstructured":"ArhinF. F.. 2010. A single 1200 mg human equivalent (HEQ) dose of oritavancin\u2014assessment of in vitro and in vivo killing of Staphylococcus aureus strains, abstr. E-1567. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA, 12 to 15 September 2010."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.07.010"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01513-07"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp286"},{"key":"e_1_3_2_9_2","volume-title":"Vancomycin injection. Package insert.","author":"Baxter Healthcare Corporation","year":"2008","unstructured":"Baxter Healthcare Corporation. 2008. Vancomycin injection. Package insert. Baxter Healthcare Corporation, Deerfield, IL."},{"key":"e_1_3_2_10_2","unstructured":"BelleyA.. 2010. Is there a relationship between oritavancin in vitro microbiological parameters and clinical outcome in a 2007\u20132008 phase 2 study of complicated skin and skin-structure infections? abstr. P-934. Twentieth Eur. Congr. Clin. Microbiol. Infect. Dis. Vienna Austria 10 to 13 April 2010."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00760-10"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00361-08"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00766-08"},{"key":"e_1_3_2_14_2","volume-title":"A1-1359. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother.","author":"Belley A.","year":"2010","unstructured":"BelleyA.. 2010. Evaluation of a single 1200 mg dose of oritavancin against Staphylococcus Aureus clinical isolates in an in vitro pharmacokinetic (PK)\/pharmacodynamic (PD) model (IVPM), abstr. A1-1359. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA, 12 to 15 September 2010."},{"key":"e_1_3_2_15_2","volume-title":"A1-1288. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother.","author":"Bhavnani S. M.","year":"2009","unstructured":"BhavnaniS. M.. 2009. Use of pharmacokinetics-pharmacodynamics to support oritavancin dose selection for patients with complicated skin and skin-structure infection: clinical confirmation of proof of concept, abstr. A1-1288. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, 12 to 15 September 2009."},{"key":"e_1_3_2_16_2","first-page":"95","article-title":"Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn. Microbiol","volume":"50","author":"Bhavnani S. M.","year":"2004","unstructured":"BhavnaniS. M. OwenJ. S. LoutitJ. S. PorterS. B. AmbroseP. G.. 2004. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn. Microbiol. Infect. Dis. 50:95\u2013102.","journal-title":"Infect. Dis."},{"key":"e_1_3_2_17_2","volume-title":"A-994. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet.","author":"Bhavnani S. M.","year":"2008","unstructured":"BhavnaniS. M.. 2008. Pharmacokinetic-pharmacodynamic (PK-PD) target attainment (TA) as decision support for oritavancin (ORI) susceptibility breakpoints for Staphylococcus aureus (SA), abstr. A-994. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet., Washington, DC, 25 to 28 October 2008."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.5.1700-1706.2003"},{"key":"e_1_3_2_19_2","volume-title":"Approved standard M7-A7","author":"Clinical and Laboratory Standards Institute","year":"2006","unstructured":"Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A7, 7th ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"7"},{"key":"e_1_3_2_20_2","article-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing. Approved standard M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.","journal-title":"Approved standard M100-S18."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.1.155"},{"key":"e_1_3_2_22_2","volume-title":"A-1863. Abstr. 44th Annu. Intersci. Conf. Antimicrob. Agents Chemother.","author":"Craig W. A.","year":"2004","unstructured":"CraigW. A. AndesD. R.. 2004. Activity of oritavancin (O) versus vancomycin (V) in the neutropenic murine thigh- and lung-infection models, abstr. A-1863. Abstr. 44th Annu. Intersci. Conf. Antimicrob. Agents Chemother., Washington, DC, 30 October to 2 November 2004."},{"key":"e_1_3_2_23_2","volume-title":"Daptomycin for injection. Package insert.","author":"Cubist Pharmaceuticals","year":"2010","unstructured":"Cubist Pharmaceuticals. 2010. Daptomycin for injection. Package insert. Cubist Pharmaceuticals, Lexington, MA."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1086\/431675"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.148-152.2005"},{"key":"e_1_3_2_26_2","unstructured":"Food and Drug Administration. 2010 posting date. Guidance for industry acute bacterial skin and skin structure infections: developing drugs for treatment (DRAFT GUIDANCE). U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Silver Spring MD."},{"key":"e_1_3_2_27_2","unstructured":"Food and Drug Administration. 1998. Guidance for industry: uncomplicated and complicated skin and skin structure infections\u2014developing antimicrobial drugs for treatment. Food and Drug Administration Silver Spring MD."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki241"},{"key":"e_1_3_2_29_2","volume-title":"L-1514. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother (ICAAC)-Infect. Dis. Soc. Am. (ISDA) 46th Annu. Meet.","author":"Hartman C. S.","year":"2008","unstructured":"HartmanC. S. WasilewskiM. M. BatesB. M.. 2008. Oritavancin in the treatment of complicated skin and skin structure infections (cSSSI): combined results of two phase 3 multinational trials, abstr. L-1514. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother (ICAAC)-Infect. Dis. Soc. Am. (ISDA) 46th Annu. Meet., Washington, DC, 25 to 28 October 2008."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00360-08"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2008.01.031"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.15.1763"},{"key":"e_1_3_2_33_2","volume-title":"B-1324. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother.","author":"Lehoux D.","year":"2009","unstructured":"LehouxD.. 2009. Comparative efficacy of oritavancin against methicillin-sensitive and -resistant Staphylococcus aureus strains in a neutropenic mouse thigh-infection model, abstr. B-1324. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, 12 to 15 September 2009."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2008.02035.x"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp126"},{"key":"e_1_3_2_36_2","volume-title":"P-936. Twentieth Eur. Congr. Clin. Microbiol. Infect. Dis.","author":"Moeck G.","year":"2010","unstructured":"MoeckG. MilataA. F. F. J. McClureT. WalkerK. J. ParrJ. T.. 2010. Comparison of oritavancin activity against Staphylococcus aureus isolates from a 2007\u20132008 phase 2 study and from 1999\u20132002 phase 3 studies of complicated skin and skin structure infection, abstr. P-936. Twentieth Eur. Congr. Clin. Microbiol. Infect. Dis., Vienna, Austria, 10 to 13 April 2010."},{"key":"e_1_3_2_37_2","volume-title":"Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother (ICAAC)-Infect. Dis. Soc. Am. (ISDA) 46th Annu. Meet.","author":"Moriarty S.","year":"2008","unstructured":"MoriartyS. WasilewskiM. M. RosenA. PerryM.. 2008. Incidence of histamine-like infusion reactions (HLIRs) in 2 phase 3 studies comparing oritavancin (ORI) with vancomycin (VAN) in the treatment of complicated skin and skin structure infections (cSSSI), poster L-1515. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother (ICAAC)-Infect. Dis. Soc. Am. (ISDA) 46th Annu. Meet., Washington, DC, 25 to 28 October 2008."},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01146-08"},{"key":"e_1_3_2_39_2","volume-title":"A1-1287. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother.","author":"Okusanya O. O.","year":"2009","unstructured":"OkusanyaO. O.. 2009. Pharmacokinetics (PK) and pharmacokinetics-pharmacodynamics of oritavancin against Staphylococcus aureus using data from a neutropenic murine thigh-infection model, abstr. A1-1287. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2009.06.064"},{"key":"e_1_3_2_41_2","volume-title":"Linezolid for injection. Prescribing information.","author":"Pfizer, Inc","year":"2010","unstructured":"Pfizer, Inc. 2010. Linezolid for injection. Prescribing information. Pfizer, Inc., New York, NY."},{"key":"e_1_3_2_42_2","volume-title":"O152. Eighteenth Eur. Congr. Clin. Microbiol. Infect. Dis.","author":"Rubino C. M.","year":"2008","unstructured":"RubinoC. M.. 2008. Use of pharmacokinetic-pharmacodynamic principles for decision support for short-course oritavancin dosing regimens for complicated skin and skin structure infections, abstr. O152. Eighteenth Eur. Congr. Clin. Microbiol. Infect. Dis., Barcelona, Spain."},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00231-09"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1086\/497143"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1086\/340353"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1086\/587896"},{"key":"e_1_3_2_47_2","volume-title":"Telavancin for injection. Prescribing information.","author":"Theravance, Inc","year":"2009","unstructured":"Theravance, Inc. 2009. Telavancin for injection. Prescribing information. Theravance, Inc., San Francisco, CA."},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.6.2260-2266.2005"},{"key":"e_1_3_2_49_2","author":"World Health Organization","year":"2001","unstructured":"World Health Organization. 2001. Global strategy for the containment of antimicrobial resistance. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/csr\/resources\/publications\/drugresist\/en\/EGlobal_Strat.pdf.","journal-title":"Global strategy for the containment of antimicrobial resistance."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00029-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00029-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:32:23Z","timestamp":1645486343000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00029-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.1128\/AAC.00029-11"],"URL":"https:\/\/doi.org\/10.1128\/aac.00029-11","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"2011-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-04-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-06-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}